Patent applications for HIV prevention drug opposed in India
A Gilead Sciences, Inc. office is shown in Foster City, California. File | Photo Credit: Reuters The Indian Patent Office is set to hear the objections against the grant of patent claims filed by U.S.-based pharmaceutical company Gilead Sciences on the HIV drug Lenacapavir later this week. Lenacapavir, administered as twice-yearly injections, has garnered attention…
Read More “Patent applications for HIV prevention drug opposed in India” »
